PAVmed (PAVM)
(Delayed Data from NSDQ)
$1.61 USD
-0.04 (-2.42%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $1.58 -0.03 (-1.86%) 6:20 PM ET
2-Buy of 5 2
F Value B Growth B Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
PAVM 1.61 -0.04(-2.42%)
Will PAVM be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for PAVM based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for PAVM
Why PAVmed Inc. (PAVM) Dipped More Than Broader Market Today
New Strong Buy Stocks for March 27th
PAVM: What are Zacks experts saying now?
Zacks Private Portfolio Services
Here's Why PAVmed Inc. (PAVM) Is a Great 'Buy the Bottom' Stock Now
PAVmed Inc. (PAVM) Upgraded to Buy: Here's Why
PAVmed Inc. (PAVM) Upgraded to Strong Buy: Here's What You Should Know
Other News for PAVM
Lucid Diagnostics to be deconsolidated from PAVmed's financial statements
PAVmed Announces Efforts to Regain Compliance with Nasdaq Listing Requirements
PAVmed announces efforts to regain Nasdaq compliance
PAVmed’s Strategic Overhaul to Secure Nasdaq Compliance
Lucid Diagnostics to Host Symposium on Non-Endoscopic Esophageal Precancer Screening at the 20th International Society for Diseases of the Esophagus (ISDE) World Congress